EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Reprogramming tumor microenvironment via systemic delivery of TLR3 agonist and manganese nanoparticle

Young Seok Cho iD, Xingwu Zhou iD, Xiaoqi Sun, Ziye Wan iD, Julia Crowther iD, Mariko Takahashi iD, Swetha Kodamasimham, Qi Wu iD, May Thazin Phoo, Youngseo Na iD, Kai Han, Zaiye Li und 4 weitere

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2409559121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Young Seok Cho und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109. Hauptthemen laut MEDLINE: Toll-Like Receptor 3, Tumor Microenvironment, Manganese, Nanoparticles. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HHS | NIH | National Institute of Dental and Craniofacial Research (NIDCR), NINDS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Toll-like receptor (TLR) agonists, as potent immunostimulatory adjuvants, play a critical role in linking the innate and adaptive immune responses. However, their antitumor effects as cancer immunotherapeutic agents have been limited. Here, we report our finding that manganese ion (Mn 2+ ) potentiates various TLR agonists, leading to robust activation of the TLR pathway and the stimulator of interferon genes (STING) pathway among innate immune cells. In particular, we have observed robust antitumor efficacy after intratumoral administration of a TLR3 agonist and Mn 2+ . To achieve systemic codelivery of TLR3 agonist and Mn 2+ , we have developed a low-molecular-weight poly(inosinic:cytidylic acid)-Mn 2+ coordination lipid nanoparticle (PLCMP). When administered intravenously in tumor-bearing mice, PLCMP successfully accumulated in tumor, induced innate immune activation, generated tumor-specific T cells, and exerted antitumor efficacy in TLR3- and STING-dependent manner without triggering overt toxicity. Moreover, PLCMP in combination with α-PD-1 therapy achieved long-lasting antitumor efficacy in multiple murine tumor models. Furthermore, vaccination with PLCMP carrying TC-1 tumor antigen peptide elicited strong antigen-specific CD8 + T cell responses and remodeled the tumor microenvironment, resulting in robust therapeutic efficacy. Overall, these results show that simultaneous activation of the TLR3 and STING pathways via PLCMP provides a promising strategy for immunotherapy and vaccination against cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 3Tumor MicroenvironmentManganeseNanoparticlesAnimalsMiceImmunity, InnateCell Line, TumorMice, Inbred C57BLFemaleHumansImmunotherapy

Stichwörter der Autor:innen

STINGTLRcancer vaccinenanoparticle

Substanzen

Toll-Like Receptor 3ManganeseTLR3 protein, mouse

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109.
  • Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109.
  • Department of Medicinal Chemistry, University of Michigan, Ann Arbor, MI 48109.
  • State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
  • Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
  • Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109.

ORCID-Profile: Young Seok Cho, Xingwu Zhou, Ziye Wan, Julia Crowther, Mariko Takahashi, Qi Wu, Youngseo Na, James J Moon

Förderung

  • HHS | NIH | National Institute of Dental and Craniofacial Research (NIDCR)
  • NINDS NIH HHS
  • NCI NIH HHS
  • NIDCR NIH HHS
  • HHS | NIH | NIDDK | Division of Diabetes, Endocrinology, and Metabolic Diseases (DEM)
  • NIDDK NIH HHS
  • NIAID NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Cho, Y. S., Zhou, X., Sun, X., Wan, Z., Crowther, J., Takahashi, M., Kodamasimham, S., Wu, Q., Phoo, M. T., Na, Y., Han, K., Li, Z., Schwendeman, A., Schwendeman, S. P., Lei, Y. L., & Moon, J. J. (2025). Reprogramming tumor microenvironment via systemic delivery of TLR3 agonist and manganese nanoparticle. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2409559121

Vancouver

Cho YS, Zhou X, Sun X, Wan Z, Crowther J, Takahashi M, et al. Reprogramming tumor microenvironment via systemic delivery of TLR3 agonist and manganese nanoparticle. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2409559121

BibTeX
@article{Cho2025,
  author = {Cho, Young Seok and Zhou, Xingwu and Sun, Xiaoqi and Wan, Ziye and Crowther, Julia and Takahashi, Mariko and Kodamasimham, Swetha and Wu, Qi and Phoo, May Thazin and Na, Youngseo and Han, Kai and Li, Zaiye and Schwendeman, Anna and Schwendeman, Steven P and Lei, Yu Leo and Moon, James J},
  title = {Reprogramming tumor microenvironment via systemic delivery of TLR3 agonist and manganese nanoparticle},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2409559121}
}
Kostenlos starten →